Publication
Integrative clinical genomics of advanced prostate cancer.
Authors not recorded
Cell2015PMID 26000489PMC4484602stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerMalignant Prostate Neoplasmcivic_curation1.00
- cancerProstate Adenocarcinomacbioportal_study1.00
- drugBicalutamidecivic_curation1.00
- drugCyproterone Acetatecivic_curation1.00
- drugFlutamidecivic_curation1.00
- drugNilutamidecivic_curation1.00
- geneARcivic_curation1.00
- variantAR Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26000489
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| AR Mutation1 | ||||||||
| Bicalutamide + Cyproterone Acetate + Flutamide + NilutamideSubstitutes | Malignant Prostate Neoplasm | Predictive | B | Supports Resistance | 4 | accepted | EID1521In a study of 150 patients with metastatic castration resistant prostate cancer (mCRPC), 71.3% of cases (n=107) harbored androgen receptor (AR) pathway aberrations. Within the AR mutation cohort, 78… (full text at CIViC) PMID 26000489 · Robinson et al., 2015 · Open in CIViC | civic |